Categories
Change Password!
Reset Password!
The new modified
formulation of Adalimumab was found to be effective in reducing overall pain and pain at needle insertion or drug injection
in rheumatoid arthritis patients, founds the latest study.
According to a
recent analysis by Tomohiko Yoshida and colleagues, the latest formulation of
Adalimumab significantly reduces the RA burden, enhances the treatment's
adherence quality, less pain during needle insertion and improves the treatment
outcomes. Adalimumab is a TNF-alpha blocker delivered via subcutaneous
injection. However, the drug is associated with the risk of serious infections
and pain at the injection site. This study involved the optimization of a
change in the existing Adalimumab on pain, outcomes and treatment outcomes.
All outcomes
displayed a considerable difference (p < 0.001). Paired t-tests were applied
as well. Injection pain with influenza vaccine and the present formulation were
reported by 68% and 80% of the patients, respectively. Although, the ratio of
the patients who felt pain with the new Adalimumab reduced to 20%.
Modern Rheumatology
New Adalimumab formulation associated with less injection site pain and improved motivation for treatment
Tomohiko Yoshida et al.
Comments (0)